Stem cell company grants worldwide non-exclusive rights to Thermo Fisher to manufacture and distribute its proprietary cell culture medium and ancillary products and methods
Stem cell company Accellta has granted worldwide non-exclusive rights to Thermo Fisher to manufacture and distribute its proprietary cell culture medium and ancillary products and methods. Accellta's patented technology is an important addition to stem cell growth, expansion and manufacturing technologies. It was designed to enable the homogenous growth of stem cell production by culturing the cells in feeder-, serum- and xeno-free media.
The company's approach to culturing pluripotent and differentiated stem cells in feeder-free conditions has been experimentally validated in numerous stem cell lines, including embryonic and induced human pluripotent stem cells.
‘Enabling consistent and robust cell growth and expansion, while reducing the costs of stem cell products, are key technological challenges facing the stem cell industry, and some of the main goals of Accellta's revolutionary technologies,' said Dr Itzchak Angel, Accellta Chairman and Chief Executive Officer. 'We believe this agreement will maximise the global reach of our solutions and make a significant impact on the robust and cost-effective use of stem cell-based products for research and regenerative medicine.’
Accellta is currently focused on creating strategic partnerships with biopharmaceutical and stem cell companies to develop large-scale and cost-effective tailor-made manufacturing processes for cell products. The company also plans to expand the use of its technologies for potential therapeutic applications of stem cells.